Symbols / EQ $2.47 +19.32%
EQ Chart
About
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 150.41M |
| Enterprise Value | 118.03M | Income | -24.42M | Sales | 4.39M |
| Book/sh | 0.51 | Cash/sh | 0.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 35 | IPO | — |
| P/E | — | Forward P/E | -5.17 | PEG | — |
| P/S | 34.25 | P/B | 4.84 | P/C | — |
| EV/EBITDA | -4.87 | EV/Sales | 26.87 | Quick Ratio | 10.74 |
| Current Ratio | 10.85 | Debt/Eq | 2.41 | LT Debt/Eq | — |
| EPS (ttm) | -0.58 | EPS next Y | -0.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -44.17% |
| ROE | -90.24% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.55% | Profit Margin | 0.00% | Shs Outstand | 60.89M |
| Shs Float | 29.14M | Short Float | 4.37% | Short Ratio | 4.37 |
| Short Interest | — | 52W High | 2.63 | 52W Low | 0.27 |
| Beta | 1.83 | Avg Volume | 694.37K | Volume | 4.68M |
| Target Price | $3.33 | Recom | Buy | Prev Close | $2.07 |
| Price | $2.47 | Change | 19.32% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.33
Mean price target
2. Current target
$2.47
Latest analyst target
3. DCF / Fair value
$-3.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.47
Low
$1.00
High
$5.00
Mean
$3.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | init | Roth Capital | — → Buy | $12 |
| 2025-03-28 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2024-11-01 | down | Jones Trading | Buy → Hold | — |
| 2024-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-12-26 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-13 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-08-14 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-01 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2023-03-24 | main | Stifel | — → Buy | $7 |
| 2023-02-08 | main | SVB Leerink | — → Outperform | $7 |
| 2022-09-27 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2022-09-08 | main | SVB Leerink | — → Outperform | $12 |
| 2022-03-24 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2022-01-05 | main | SVB Leerink | — → Outperform | $14 |
| 2021-09-15 | init | Cantor Fitzgerald | — → Overweight | $14 |
News
RSS: Latest EQ news- State regulators open probe of $400M stock sale between New Mexico utility and private equity firm - Source New Mexico hu, 12 Mar 2026 18
- The Best Global Equity Funds and ETFs to Buy - Morningstar Fri, 13 Mar 2026 16
- $EQ stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Fri, 13 Mar 2026 14
- Experimental colitis pill gets $35M boost, funded into 2029 - Stock Titan Fri, 13 Mar 2026 12
- India's equity benchmarks confirm correction on Iran war, crude prices; technicals weaken - Reuters Fri, 13 Mar 2026 10
- Equillium (EQ) Receives Buy Rating from Roth Capital | EQ Stock News - GuruFocus Fri, 13 Mar 2026 18
- Leverage Shares by Themes Debuts WLDU, Delivering 2X Global Equity Exposure, and GLWG Single-Stock ETF - Yahoo Finance ue, 10 Mar 2026 13
- Private credit anxiety weigh on private equity, asset manager stocks (OWL:NYSE) - Seeking Alpha hu, 12 Mar 2026 17
- Northern Oil & Gas stock falls on equity offering pricing - Investing.com hu, 12 Mar 2026 18
- Equillium (NASDAQ:EQ) COO Sells $362,438.00 in Stock - MarketBeat hu, 12 Mar 2026 00
- Why EQ Resources (ASX:EQR) Is Up 5.8% After Narrowing Half-Year Loss On Stronger Revenue – And What's Next - simplywall.st Sat, 14 Mar 2026 12
- Private equity stocks down 30-40% in three months, bigger worry than geopolitical risk - 24/7 Wall St. Wed, 11 Mar 2026 20
- Kosmos Energy Stock Pre-Market (-10%): Prices Dilutive Equity Offering at $1.90 - Trefis Wed, 11 Mar 2026 06
- A New Dawn for Non-US Stocks? Rethinking Global Equity Allocations - AllianceBernstein Fri, 23 Jan 2026 08
- Why EQ Resources Shares Are Quietly Climbing Now - TipRanks Fri, 13 Mar 2026 03
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 181219 | 362438 | — | Sale at price 2.00 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-03-09 00:00:00 | D |
| 1 | 152361 | 119603 | — | Conversion of Exercise of derivative security at price 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-03-09 00:00:00 | D |
| 2 | 185937 | 328104 | — | Sale at price 1.74 - 1.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-02-19 00:00:00 | D |
| 3 | 185937 | 328104 | — | Sale at price 1.74 - 1.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-02-19 00:00:00 | D |
| 4 | 185937 | 141750 | — | Conversion of Exercise of derivative security at price 0.73 - 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-02-19 00:00:00 | D |
| 5 | 185937 | 141750 | — | Conversion of Exercise of derivative security at price 0.73 - 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-02-19 00:00:00 | D |
| 6 | 6533 | 8428 | — | Sale at price 1.29 per share. | TOM PENNY | Officer | — | 2026-01-08 00:00:00 | D |
| 7 | 100000 | 150000 | — | Sale at price 1.50 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-23 00:00:00 | D |
| 8 | 100000 | 78500 | — | Conversion of Exercise of derivative security at price 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-23 00:00:00 | D |
| 9 | 35704 | 47486 | — | Sale at price 1.31 - 1.34 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -7.57M | -12.14M | -38.21M | -37.91M |
| TotalUnusualItems | 0.00 | -23.05M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -23.05M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.07M | -13.34M | -62.43M | -39.05M |
| ReconciledDepreciation | 137.00K | 126.00K | 118.00K | 72.00K |
| EBITDA | -7.57M | -12.14M | -61.26M | -37.91M |
| EBIT | -7.71M | -12.26M | -61.38M | -37.98M |
| NetInterestIncome | 1.38M | 1.84M | -633.00K | -1.02M |
| InterestExpense | 0.00 | 491.00K | 1.05M | 1.07M |
| InterestIncome | 1.38M | 2.33M | 420.00K | 57.00K |
| NormalizedIncome | -8.07M | -13.34M | -39.38M | -39.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.07M | -13.34M | -62.43M | -39.05M |
| TotalExpenses | 49.36M | 50.61M | 54.79M | 37.79M |
| TotalOperatingIncomeAsReported | -8.27M | -14.52M | -62.08M | -37.79M |
| DilutedAverageShares | 35.36M | 34.73M | 33.73M | 28.81M |
| BasicAverageShares | 35.36M | 34.73M | 33.73M | 28.81M |
| DilutedEPS | -0.23 | -0.38 | -1.85 | -1.36 |
| BasicEPS | -0.23 | -0.38 | -1.85 | -1.36 |
| DilutedNIAvailtoComStockholders | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeCommonStockholders | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncome | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeIncludingNoncontrollingInterests | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeContinuousOperations | -8.07M | -13.34M | -62.43M | -39.05M |
| TaxProvision | 361.00K | 580.00K | 0.00 | |
| PretaxIncome | -7.71M | -12.76M | -62.43M | -39.05M |
| OtherIncomeExpense | -818.00K | -76.00K | -22.77M | -250.00K |
| OtherNonOperatingIncomeExpenses | -818.00K | -76.00K | 281.00K | -250.00K |
| SpecialIncomeCharges | 0.00 | -23.05M | 0.00 | |
| OtherSpecialCharges | 23.05M | |||
| NetNonOperatingInterestIncomeExpense | 1.38M | 1.84M | -633.00K | -1.02M |
| InterestExpenseNonOperating | 0.00 | 491.00K | 1.05M | 1.07M |
| InterestIncomeNonOperating | 1.38M | 2.33M | 420.00K | 57.00K |
| OperatingIncome | -8.27M | -14.52M | -39.03M | -37.79M |
| OperatingExpense | 49.36M | 50.61M | 54.79M | 37.79M |
| ResearchAndDevelopment | 37.43M | 37.04M | 37.55M | 26.38M |
| SellingGeneralAndAdministration | 11.94M | 13.57M | 17.24M | 11.41M |
| GeneralAndAdministrativeExpense | 11.94M | 13.57M | 17.24M | 11.41M |
| OtherGandA | 11.94M | 13.57M | 17.24M | 11.41M |
| TotalRevenue | 41.09M | 36.08M | 15.76M | 0.00 |
| OperatingRevenue | 41.09M | 36.08M | 15.76M | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 35.56M | 35.25M | 34.41M | 29.46M |
| ShareIssued | 35.56M | 35.25M | 34.41M | 29.46M |
| TotalDebt | 384.00K | 824.00K | 10.19M | 11.79M |
| TangibleBookValue | 19.06M | 22.57M | 31.94M | 66.50M |
| InvestedCapital | 19.06M | 22.57M | 40.90M | 76.68M |
| WorkingCapital | 18.62M | 21.78M | 44.70M | 74.45M |
| NetTangibleAssets | 19.06M | 22.57M | 31.94M | 66.50M |
| CapitalLeaseObligations | 384.00K | 824.00K | 1.23M | 1.61M |
| CommonStockEquity | 19.06M | 22.57M | 31.94M | 66.50M |
| TotalCapitalization | 19.06M | 22.57M | 35.18M | 75.25M |
| TotalEquityGrossMinorityInterest | 19.06M | 22.57M | 31.94M | 66.50M |
| StockholdersEquity | 19.06M | 22.57M | 31.94M | 66.50M |
| GainsLossesNotAffectingRetainedEarnings | 781.00K | 140.00K | 76.00K | -138.00K |
| OtherEquityAdjustments | 781.00K | 140.00K | 76.00K | -138.00K |
| RetainedEarnings | -193.81M | -185.74M | -172.41M | -109.98M |
| AdditionalPaidInCapital | 212.08M | 208.17M | 204.27M | 176.62M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 2.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 6.54M | 27.96M | 46.48M | 18.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 187.00K | 384.00K | 14.44M | 9.98M |
| NonCurrentDeferredLiabilities | 0.00 | 10.38M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 10.38M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 187.00K | 384.00K | 4.06M | 9.98M |
| LongTermCapitalLeaseObligation | 187.00K | 384.00K | 824.00K | 1.24M |
| LongTermDebt | 3.24M | 8.75M | ||
| CurrentLiabilities | 6.36M | 27.57M | 32.04M | 8.91M |
| CurrentDeferredLiabilities | 0.00 | 15.73M | 14.70M | 0.00 |
| CurrentDeferredRevenue | 0.00 | 15.73M | 14.70M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 197.00K | 440.00K | 6.12M | 1.80M |
| CurrentCapitalLeaseObligation | 197.00K | 440.00K | 408.00K | 376.00K |
| CurrentDebt | 5.71M | 1.43M | ||
| OtherCurrentBorrowings | 5.71M | 1.43M | ||
| PayablesAndAccruedExpenses | 6.16M | 11.40M | 11.22M | 7.11M |
| CurrentAccruedExpenses | 3.12M | 6.70M | 7.24M | 5.89M |
| InterestPayable | 0.00 | 74.00K | 71.00K | |
| Payables | 3.04M | 4.71M | 3.98M | 1.23M |
| TotalTaxPayable | 365.00K | 0.00 | ||
| IncomeTaxPayable | 365.00K | 0.00 | ||
| AccountsPayable | 2.68M | 4.71M | 3.98M | 1.23M |
| TotalAssets | 25.60M | 50.53M | 78.42M | 85.41M |
| TotalNonCurrentAssets | 626.00K | 1.18M | 1.69M | 2.04M |
| OtherNonCurrentAssets | 70.00K | 104.00K | 153.00K | |
| NetPPE | 626.00K | 1.11M | 1.58M | 1.88M |
| AccumulatedDepreciation | -499.00K | -364.00K | -249.00K | -147.00K |
| GrossPPE | 1.12M | 1.48M | 1.83M | 2.03M |
| Leases | 20.00K | 20.00K | 20.00K | 0.00 |
| OtherProperties | 364.00K | 796.00K | 1.19M | 1.65M |
| MachineryFurnitureEquipment | 741.00K | 659.00K | 620.00K | 384.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 24.98M | 49.35M | 76.73M | 83.37M |
| OtherCurrentAssets | 429.00K | 235.00K | 8.00K | 2.66M |
| PrepaidAssets | 830.00K | 1.96M | 1.59M | 2.66M |
| Receivables | 1.14M | 6.29M | 4.11M | 0.00 |
| OtherReceivables | 178.00K | 497.00K | 269.00K | |
| TaxesReceivable | 966.00K | 2.05M | 1.01M | |
| AccountsReceivable | 0.00 | 3.73M | 2.84M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 22.57M | 40.87M | 71.02M | 80.71M |
| OtherShortTermInvestments | 4.49M | 17.65M | 11.92M | 30.34M |
| CashAndCashEquivalents | 18.09M | 23.22M | 59.11M | 50.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.11M | -21.83M | -9.01M | -32.14M |
| RepurchaseOfCapitalStock | 0.00 | -260.00K | 0.00 | |
| RepaymentOfDebt | 0.00 | -9.13M | -1.43M | |
| IssuanceOfCapitalStock | 0.00 | 29.91M | ||
| CapitalExpenditure | -85.00K | -50.00K | -279.00K | -57.00K |
| InterestPaidSupplementalData | 0.00 | 946.00K | 847.00K | 836.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 580.00K | 0.00 | |
| EndCashPosition | 18.09M | 23.22M | 59.11M | 50.37M |
| BeginningCashPosition | 23.22M | 59.11M | 50.37M | 23.98M |
| EffectOfExchangeRateChanges | -83.00K | -118.00K | 5.00K | -2.00K |
| ChangesInCash | -5.05M | -35.77M | 8.74M | 26.39M |
| FinancingCashFlow | 164.00K | -9.23M | -1.22M | 31.06M |
| CashFlowFromContinuingFinancingActivities | 164.00K | -9.23M | -1.22M | 31.06M |
| ProceedsFromStockOptionExercised | 164.00K | 165.00K | 214.00K | 1.15M |
| NetCommonStockIssuance | 0.00 | -260.00K | 0.00 | 29.91M |
| CommonStockPayments | 0.00 | -260.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 29.91M | ||
| NetIssuancePaymentsOfDebt | 0.00 | -9.13M | -1.43M | |
| NetLongTermDebtIssuance | 0.00 | -9.13M | -1.43M | |
| LongTermDebtPayments | 0.00 | -9.13M | -1.43M | |
| InvestingCashFlow | 13.81M | -4.76M | 18.68M | 27.41M |
| CashFlowFromContinuingInvestingActivities | 13.81M | -4.76M | 18.68M | 27.41M |
| NetInvestmentPurchaseAndSale | 13.90M | -4.71M | 18.26M | 27.46M |
| SaleOfInvestment | 31.50M | 50.00M | 33.23M | 60.45M |
| PurchaseOfInvestment | -17.60M | -54.71M | -14.96M | -32.99M |
| NetBusinessPurchaseAndSale | 0.00 | 700.00K | 0.00 | |
| SaleOfBusiness | 0.00 | 700.00K | 0.00 | |
| NetPPEPurchaseAndSale | -85.00K | -50.00K | -279.00K | -57.00K |
| PurchaseOfPPE | -85.00K | -50.00K | -279.00K | -57.00K |
| OperatingCashFlow | -19.03M | -21.78M | -8.73M | -32.08M |
| CashFlowFromContinuingOperatingActivities | -19.03M | -21.78M | -8.73M | -32.08M |
| ChangeInWorkingCapital | 842.00K | -2.55M | 19.00K | 1.70M |
| ChangeInOtherWorkingCapital | -9.00K | -13.00K | 75.00K | -37.00K |
| ChangeInOtherCurrentLiabilities | -151.00K | |||
| ChangeInOtherCurrentAssets | 114.00K | |||
| ChangeInPayablesAndAccruedExpense | -5.16M | 169.00K | 2.94M | 1.52M |
| ChangeInAccruedExpense | -3.16M | -554.00K | 432.00K | 3.10M |
| ChangeInPayable | -2.00M | 723.00K | 2.51M | -1.58M |
| ChangeInAccountPayable | -2.00M | 723.00K | 2.51M | -1.58M |
| ChangeInPrepaidAssets | 2.27M | -1.80M | -158.00K | 214.00K |
| ChangeInReceivables | 3.73M | -897.00K | -2.84M | 0.00 |
| ChangesInAccountReceivables | 3.73M | -897.00K | -2.84M | 0.00 |
| OtherNonCashItems | -15.73M | -9.17M | 48.33M | 237.00K |
| StockBasedCompensation | 3.75M | 4.00M | 4.84M | 4.41M |
| AmortizationOfSecurities | -754.00K | -914.00K | 127.00K | 314.00K |
| DepreciationAmortizationDepletion | 137.00K | 126.00K | 118.00K | 72.00K |
| DepreciationAndAmortization | 137.00K | 126.00K | 118.00K | 72.00K |
| Depreciation | 137.00K | 126.00K | 118.00K | |
| OperatingGainsLosses | 794.00K | 58.00K | 260.00K | 240.00K |
| NetForeignCurrencyExchangeGainLoss | 794.00K | 58.00K | 260.00K | 240.00K |
| NetIncomeFromContinuingOperations | -8.07M | -13.34M | -62.43M | -39.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EQ
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|